natgillin/translations-raw huggingface dataset:
The composition of any of claims 1 to 6 wherein the coating comprises polyethylene glycol, propylene glycol, sorbitol, glycerol, maltitol, xylitol, mannitol, erythritol, glycerol trioleate, tributyl citrate, triethyl citrate acetyl triethyl citrate, glyceryl triacetate, stearic acid, medium chain triglycerides or a mixture thereof as plasticizer. 
Pripravak prema bilo kojem od zahtjeva 1 do 7 naznačen time da premaz kao plastifikator sadrži polietilen glikol, propilen glikol, sorbitol, glicerol, maltitol, ksilitol, manitol, eritritol, glicerol trioleat, tributil citrat, trietil citrat, acetil trietil citrat, gliceril triacetat, stearinsku kiselinu, trigliceride srednjeg lanca ili njihovu smjesu.
The composition of claim 11 comprising regorafenib in an amorphous state and a pharmaceutically acceptable matrix wherein the matrix comprises polyvinylpyrrolidone, vinylpyrrolidone/vinylacetate copolymer, polyalkylene glycol, hydroxyalkyl, hydroxyalkyl methyl cellulose, carboxymethyl cellulose, sodium carboxymethyl cellulose, ethyl cellulose, polymethacrylates, polyvinyl alcohol, polyvinyl acetate, vinyl alcohol/vinyl acetate copolymer, polyglycolized glycerides, xanthan gum, carrageenan, chitosan, chitin, polydextrin, dextrin, starch, proteins, sucrose, lactose, fructose, maltose, raffinose, sorbitol, lactitol, mannitol, maltitol, erythritol, inositol, trehalose, isomalt, inulin, maltodextrin, ß-cyclodextrin, hydroxypropyl-ß-cyclodextrin or sulfobutyl ether cyclodextrin or a mixture thereof. 
Pripravak prema zahtjevu 11 koji sadrži regorafenib u amorfnom stanju i farmaceutski prihvatljivu matricu naznačen time da matrica sadrži polivinilpirolidon, kopolimer vinilpirolidon/vinilacetat, polialkilen glikol, hidroksialkil, hidroksialkil metil celulozu, karboksimetil celulozu, natrijevu karboksimetil celulozu, etil celulozu, polimetakrilate, polivinil alkohol, polivinil acetat, kopolimer vinil alkohol/vinil acetat, poliglikolizirane gliceride, ksantan gumu, karagenan, kitosan, kitin, polidekstrin, dekstrin, škrob, proteine, sukrozu, laktozu, fruktozu, maltozu, rafinozu, sorbitol, laktitol, manitol, maltitol, eritritol, inositol, trehalozu, izomalt, inulin, maltodekstrin, ß-ciklodekstrin, hidroksipropil-ß-ciklodekstrin ili sulfobutil eter ciklodekstrin ili njihovu smjesu.
Filtering apparatus (1) according to the preceding claim, characterised in that said filtering means comprise one or more monolithic ceramic elements (13, 23) with wall flow. 
Uređaj za filtriranje (1) prema prethodnom zahtjevu, naznačen time što filteri obuhvaćaju jedan ili više monolitnih keramičkih elemenata (13, 23) sa zidnim protokom.
Filtering apparatus (1) according to the preceding claim, characterised in that there are more than two of said monolithic ceramic elements and that they are arranged parallel to each other with respect to the flow of gas passing through the compartment. 
Uređaj za filtriranje (1) prema prethodnom zahtjevu, naznačen time što postoje više od dva takva monolitna keramička elementa i što su međusobno raspoređeni paralelno s obzirom na protok plina koji prolazi odjeljkom.
Filtering apparatus (1) according to one or more of the preceding claims, characterised in that said emission means comprise injectors (14, 24) and ejectors (15, 25) that generate a countercurrent gas pulse flow at said filtering means (13, 23), which removes the ash accumulated on the filters. 
Uređaj za filtriranje (1) prema jednom ili više od prethodnih zahtjeva, naznačen time što navedena emisijska sredstva obuhvaćaju injektore (14, 24) i izbacivače (15, 25) koji stvaraju pulsni protok protustrujnog plina na tim filterima (13, 23), čime se uklanja pepeo nakupljen na filterima.
Filtering apparatus (1) according to claim 1, characterised in that said injector means (12, 22) further comprise means (16, 26) for the nebulisation of an oxidising reagent in an aqueous solution. 
Uređaj za filtriranje (1) prema zahtjevu 1, naznačen time što injektor (12, 22) dalje obuhvaća sredstva (16, 26) za raspršivanje (nebulizaciju) oksidacijskog reagensa u vodenoj otopini.
Filtering apparatus (1) according to one or more of the preceding claims, characterised in that each of said compartments is in communication, in its lower portion, with a hopper (100) for collecting the particulate. 
Uređaj za filtriranje (1) prema jednom ili više od prethodnih zahtjeva, naznačen time što je svaki od odjeljaka povezan, u svom donjem dijelu, s lijevkom (100) za skupljanje čestica.
acting, by means of the central control unit, on the shut-off valve (11, 21) of the compartment (10, 20) to be regenerated, operating the closure of said valve and reducing, or even stopping, the flow of the exhaust gases through said compartment; 
djelovanje, pomoću središnje kontrolne jedinice, na ventil za zatvaranje (11, 21) odjeljka (10, 20) koji se regenerira, upravljanje zatvaranjem tog ventila i smanjenje, ili čak zaustavljanje protoka ispušnih plinova kroz taj odjeljak;
operating said emission means (14, 24, 15, 25) to emit a countercurrent flow of pressurised gas or a countercurrent pulse of pressurised gas at said filtering means (13, 23); 
upravljanje emisijskim sredstvima (14, 24, 15, 25) da se ispusti protustrujni protok stlačenog plina ili protustrujni puls stlačenog plina na tim filterima (13, 23);
acting on said central shut-off valve (11, 21) of the compartment (10, 20) to be regenerated, by means of the central control unit, operating the opening of said valve thus permitting the flow of the hot gases injected through the nozzles (12, 22) to pass through said filtering means (13, 23). 
djelovanje na centralni ventil za zatvaranje (11, 21) odjeljka (10, 20) koji se regenerira, pomoću središnje kontrolne jedinice, upravljanje otvaranjem tog ventila čime se omogućava protok vrućih plinova ubačenih kroz mlaznice (12, 22) kroz navedene filtere (13, 23).
successive sieving of obtained starting material to obtain at least the following fractions: ➢ fraction F-b1 in which size of particles is of from d1 to d2; 
uzastopno prosijavanje dobivenog polaznog materijala da se dobiju barem slijedeće frakcije: [image] frakciju F-b1 u kojoj je veličina čestica od d1 do d2;
Sunflower meal fraction according to claim 11 or 12, characterised in that it contains less than 8% of crude fibers. 
Frakcija suncokretove prekrupe prema zahtjevu 11 ili 12, naznačena time da sadrži manje od 8% sirovih vlakana.
filling the suitable container with the filtrate obtained after performing step (ii), so as to thereby prepare the pharmaceutical preparation of glatiramer acetate and mannitol in the suitable container. 
punjenje prikladnog spremnika filtratom dobivenim nakon izvođenja stupnja (ii), tako da se time pripremi farmaceutski pripravak glatiramer acetata i manitola u prikladnom spremniku.
The process of claim 1, wherein the filtering step (ii) comprises filtering the aqueous pharmaceutical solution through a first filter, or a first filter and a second filter. 
Postupak prema patentnom zahtjevu 1, naznačen time, da stupanj filtriranja (ii) sadrži filtriranje vodene farmaceutske otopine kroz prvi filter, ili prvi filter i drugi filter.
The process of any one of claims 2-4, wherein the filtering step (ii) further comprises the step of receiving the aqueous pharmaceutical solution filtered through the first filter in a receiving vessel, and further comprises the step of reducing the temperature of the aqueous pharmaceutical solution to a temperature from above 0°C up to 17.5°C after leaving the receiving vessel and before entering into the second filter. 
Postupak prema bilo kojem od patentnih zahtjeva 2-4, naznačen time, da stupanj filtriranja (ii) nadalje sadrži stupanj primanja vodene farmaceutske otopine filtrirane kroz prvi filter u prihvatnu posudu, i nadalje sadrži stupanj smanjivanja temperature vodene farmaceutske otopine na temperaturu od iznad 0°C do 17,5°C, nakon izlaska iz prihvatne posude, a prije ulaska u drugi filter.
compounding the aqueous pharmaceutical solution in a compounding vessel; 
miješanje vodene farmaceutske otopine u posudi za miješanje;
compounding the aqueous pharmaceutical solution in a compounding vessel and reducing the temperature of the aqueous pharmaceutical solution to a temperature from above 0°C up to 17.5°C after leaving the compounding vessel and before entering into the first filter; or 
miješanje vodene farmaceutske otopine u posudi za miješanje i smanjivanje temperature vodene farmaceutske otopine na temperaturu od iznad 0°C do 17,5°C, nakon izlaska iz posude za miješanje, a prije ulaska u prvi filter; ili
compounding the aqueous pharmaceutical solution in a compounding vessel and reducing the temperature of the aqueous pharmaceutical solution to a temperature from above 0°C up to 17.5°C while in the compounding vessel. 
miješanje vodene farmaceutske otopine u posudi za miješanje i smanjivanje temperature vodene farmaceutske otopine na temperaturu od iznad 0°C do 17,5°C, dok je u posudi za miješanje.
the filtering step (ii) comprises filtering the aqueous pharmaceutical solution through a first filter, or a first filter and a second filter, and wherein the aqueous pharmaceutical solution is passed through the second filter at a rate of 3-25 liters/hour; at a rate of 3-22 liters/hour; at a rate of 3-15 liters/hour; or at a rate of 3-10 liters/hour. 
stupanj filtriranja (ii) sadrži filtriranje vodene farmaceutske otopine kroz prvi filter, ili prvi filter i drugi filter, i kod čega se vodena farmaceutska otopina propušta kroz drugi filter pri brzini od 3-25 litara na sat; pri brzini od 3-22 litre na sat; pri brzini od 3-15 litara na sat; ili pri brzini od 3-10 litara na sat;
the pressure during the filtering step (ii) and the pressure during the filling step (iii) is maintained below 5.0 bar; or below 3.0 bar; or below 2.0 bar; or 
pritisak za vrijeme stupnja filtriranja (ii) i pritisak za vrijeme stupnja punjenja (iii) se održava ispod 5,0 bara; ili ispod 3,0 bara; ili ispod 2,0 bara; ili
the filtering step (ii) comprises filtering the aqueous pharmaceutical solution through a first filter, or a first filter and a second filter, and wherein the filtering is performed using a sterilizing filter having a pore size of 0.2µm or less, wherein the first, the second or both filters are a sterilizing filter having a pore size of 0.2µm or less. 
stupanj filtriranja (ii) sadrži filtriranje vodene farmaceutske otopine kroz prvi filter, ili prvi filter i drugi filter, i kod čega se filtriranje izvodi koristeći sterilizirajući filter koji ima veličinu pora od 0,2um ili manje, kod čega su prvi, drugi ili oba filtera sterilizirajući filteri, koji imaju veličinu pora od 0,2pm ili manje.
The process of any one of claims 1-12, wherein the pharmaceutical preparation in the suitable container is an aqueous pharmaceutical solution which is a sterilized aqueous solution which has been sterilized by filtration and without subjecting the aqueous pharmaceutical solution to heat, chemicals, or radiation exposure. 
Postupak prema bilo kojem od patentnih zahtjeva 1-12, naznačen time, da farmaceutski pripravak u prikladnom spremniku jest vodena farmaceutska otopina . koja je sterilizirana vodena otopina, koja je bila sterilizirana filtriranjem i bez podvrgavanja vodene farmaceutske otopine toplinskoj, kemijskoj ili radijacijskoj izloženosti.
The process of any one of claims 1-11, wherein the pharmaceutical preparation is a lyophilized powder of glatiramer acetate and mannitol, and the process further comprises a step of lyophilizing the filtrate after it has been filled into the suitable container so as to form a lyophilized powder of glatiramer acetate and mannitol in the suitable container. 
Postupak prema bilo kojem od patentnih zahtjeva 1-11, naznačen time, da farmaceutski pripravak jest liofilizirani prašak glatiramer acetata i manitola, a da postupak nadalje sadrži stupanj liofiliziranja filtrata nakon stoje taj bio napunjen u prikladni spremnik, tako da se oblikuje liofilizirani prašak glatiramer acetata i manitola u prikladnom spremniku.
The process according to claim 1, wherein 1 equivalent of n 6-1,2-dichlorobenzene- n 5-cyclopentadienyliron(II) hexafluorophosphate is mixed with 1-5 equivalent base, 1-3 equivalents 2,4-dimethylthiophenol and 1-3 equivalents piperazine in a solvent at 10°C-50°C to obtain the compound of the formula followed by de-complexation to obtain 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazine. 
Postupak prema zahtjevu 1, gdje se 1 ekvivalent n6-1,2-diklorobenzen-n5-ciklopentadieniliron(II) heksafluorofosfata miješa s 1-5 ekvivalenata baze, 1-3 ekvivalenta 2,4-dimetiltiofenola i 1-3 ekvivalenta piperazina u otapalu na 10°C-50°C da se dobije spoj formule [image] nakon čega slijedi dekompleksacija da se dobije 1-[2-(2,4-dimetil-fenilsulfanil)-fenil]-piperazin.
The syringe of claim 1, prepared by the process wherein the filtering step (ii) comprises filtering the aqueous pharmaceutical solution through a first filter, or a first filter and a second filter. 
Postupak prema patentnom zahtjevu 1, naznačen time, da stupanj filtriranja (ii) sadrži filtriranje vodene farmaceutske otopine kroz prvi filter, ili prvi filter i drugi filter.
The syringe of any one of claims 2-4, prepared by the process wherein the filtering step (ii) further comprises the step of receiving the aqueous pharmaceutical solution filtered through the first filter in a receiving vessel, and further comprises the step of reducing the temperature of the aqueous pharmaceutical solution to a temperature from above 0°C up to 17.5°C after leaving the receiving vessel and before entering into the second filter. 
Postupak prema bilo kojem od patentnih zahtjeva 2-4, naznačen time, da stupanj filtriranja (ii) nadalje sadrži stupanj primanja vodene farmaceutske otopine filtrirane kroz prvi filter u prihvatnu posudu, i nadalje sadrži stupanj smanjivanja temperature vodene farmaceutske otopine na temperaturu od iznad 0°C do 17,5°C, nakon izlaska iz prihvatne posude, a prije ulaska u drugi filter.
The syringe of any one of claims 1-13, prepared by the process wherein the pharmaceutical preparation in the suitable container is an aqueous pharmaceutical solution which is a sterilized aqueous solution which has been sterilized by filtration and without subjecting the aqueous pharmaceutical solution. 
Postupak prema bilo kojem od patentnih zahtjeva 1-12, naznačen time, da farmaceutski pripravak u prikladnom spremniku jest vodena farmaceutska otopina . koja je sterilizirana vodena otopina, koja je bila sterilizirana filtriranjem i bez podvrgavanja vodene farmaceutske otopine toplinskoj, kemijskoj ili radijacijskoj izloženosti.
The method according to claim 1, wherein the isolated antibody or antigen-binding portion thereof comprises a light chain variable region having a sequence at least 90% identical to the amino acid sequence of SEQ ID NO: 10, and a heavy chain variable region having a sequence at least 90% identical to the amino acid sequence of SEQ ID NO:4. 
Izolirano protutijelo, ili njegov dio za vezanje na antigen, prema zahtjevu 1, naznačen/o time, da obuhvaća varijabilno područje slabog lanca koje ima sekvencu s najmanje 90% identičnosti s aminokiselinskom sekvencom od SEQ ID NO:10 i varijabilno područje jakog lanca koje ima sekvencu s najmanje 90% identičnosti s aminokiselinskom sekvencom od SEQ ID NO:4.
The method according to claim 1, wherein the isolated antibody or antigen-binding portion thereof comprises a light chain variable region having a sequence at least 90% identical to the amino acid sequence of SEQ ID NO: 11, and a heavy chain variable region having a sequence at least 90% identical to the amino acid sequence of SEQ ID NO: 5. 
Izolirano humanizirano protutijelo, ili njegov dio za vezanje na antigen, prema zahtjevu 4, naznačen/o time, da obuhvaća varijabilno područje slabog lanca koje ima sekvencu s najmanje 90% identičnosti s aminokiselinskom sekvencom od SEQ ID NO:11 i varijabilno područje jakog lanca koje ima sekvencu s najmanje 90% identičnosti s aminokiselinskom sekvencom od SEQ ID NO:5.
The applicator according to claim 2, wherein the heating unit (12) of the punch (6) includes an electric heating mat embedded into said punch. 
Aplikator u skladu s patentnim zahtjevom 1 ili 2, naznačen time, da je uređaj za grijanje (12) šila (6) izveden kao električni podmetač za grijanje koji je ugrađen u navedeno šilo.
The aqueous solution according to claim 4 or 5, wherein the at least one flavouring agent is selected from any of the cherry, lemon, lime, mandarin, orange, tangerine, mint, strawberry, banana, caramel, liquorice, passion-fruit, peach, raspberry, tutti-frutti, grapefruit, vanilla, cream, chocolate, grape flavour or mixture thereof, for example selected from the vanilla and strawberry flavour, and for example in an amount of from 0 to 5% w/V, e.g. 
Otopina prema patentnom zahtjevu 5, pri čemu je najmanje jedno sredstvo za poboljšanje okusa odabrano od bilo koje od aroma trešnje, limuna, limete, mandarine, narnače, mandarine, metvice, jagode, banane, karamele, sladića, krunica, breskve, maline, slatkiš od ražličitog voća, grejp, vanilije, vrhnje, čokolade, okus grožđa ili njihova smjesa, na primjer odabran od arome vanilije i jagode, i prisutan je u iznosu od 0 do 5% tež/vol, npr.
The composition according to any one of claims 4 to 6, wherein the at least one viscosity increasing agent is selected from cellulose derivatives, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, or methylcellulose, poloxamers, from gums, guar gum, tragacanthe gum, acacia gum, xanthane gum, alginic derivatives, alginic acid, sodium alginate, polyvinylpyrrolidone, from silicates, bentonite, laponite, veegum, for example hydroxyethylcellulose, and is for example in an amount of from 0 to 15% w/V, e.g. 
Otopina prema bilo kojem od patentnih zahtjeva 5 do 7, pri čemu je najmanje jedno sredstvo za povećanje viskoznosti odabrano od derivata celuloze, hidroksietilceluloze, hidroksipropilceluloze, hidroksipropilmetilceluloze, ili metilceluloze, poloksamera, od guma, guar gume, tragantove gume, gume akacije, ksantan gume, gelan gume, alginskih derivata, alginske kiseline, natrijum alginata, polivinilpirolidona, od silikata, bentonita, laponita, veegum, specifičnije od ne-ionskih poloksamera, polivinilpirolidona i celulozni eteri, u količini od 0 do 15% tež/vol, npr.
1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine and pharmaceutically acceptable salts thereof for use in the treatment of depression or anxiety in a patient who has previously received medication for the treatment of said disease which medication was ceased due to weight related adverse events. 
-[2-(2,4-dimetil-fenilsulfanil)fenil]piperazin i njegove farmaceutski prikladne soli za uporabu u liječenju depresije ili anksioznosti u bolesnika koji je prethodno primao lijek za liječenje te bolesti, a koji je lijek prekinut zbog nuspojava vezanih uz težinu.
Use of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine and pharmaceutically acceptable salts thereof in the manufacture of a medicament for the treatment of depression or anxiety in a patient who has previously received medication for the treatment of said disease which medication was ceased due to weight related adverse events. 
Uporaba 1-[2-(2,4-dimetil-fenilsulfanil)fenil]piperazina i njegovih farmaceutski prikladnih soli u proizvodnji lijeka za liječenje depresije ili anksioznosti u bolesnika koji je prethodno primao lijek za liječenje te bolesti, a koji je lijek prekinut zbog nuspojava vezanih uz težinu.
The aqueous solution according to claim 3, wherein the at least one flavouring agent is selected from any of the cherry, lemon, lime, mandarin, orange, tangerine, mint, strawberry, banana, caramel, liquorice, passion-fruit, peach, raspberry, tutti-frutti, grapefruit, vanilla, cream, chocolate, grape flavour or mixture thereof, for example selected from the vanilla and strawberry flavour, and is present in an amount of from 0 to 5% w/V, e.g. 
Otopina prema patentnom zahtjevu 5, pri čemu je najmanje jedno sredstvo za poboljšanje okusa odabrano od bilo koje od aroma trešnje, limuna, limete, mandarine, narnače, mandarine, metvice, jagode, banane, karamele, sladića, krunica, breskve, maline, slatkiš od ražličitog voća, grejp, vanilije, vrhnje, čokolade, okus grožđa ili njihova smjesa, na primjer odabran od arome vanilije i jagode, i prisutan je u iznosu od 0 do 5% tež/vol, npr.
The aqueous solution according to claim 4, wherein the at least one flavouring agent is vanilla in an amount of from 0.01 to 0.5% w/V. 
Otopina prema patentnom zahtjevu 6, naznačen time da je najmanje jedno sredstvo za poboljšanje okusa od vanilije u količini od 0.01 do 0.5% tež/vol.
The aqueous solution according to any one of claims 4 to 5, wherein the at least one viscosity increasing agent is selected from cellulose derivatives, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, or methylcellulose, poloxamers, from gums, guar gum, tragacanthe gum, acacia gum, xanthane gum, gelane gums, alginic derivatives, alginic acid, sodium alginate, polyvinylpyrrolidone, from silicates, bentonite, laponite, veegum, more particularly from non-ionic poloxamers, polyvinylpyrrolidone and cellulose ethers, in an amount of from 0 to 15% w/V, e.g. 
Otopina prema bilo kojem od patentnih zahtjeva 5 do 7, pri čemu je najmanje jedno sredstvo za povećanje viskoznosti odabrano od derivata celuloze, hidroksietilceluloze, hidroksipropilceluloze, hidroksipropilmetilceluloze, ili metilceluloze, poloksamera, od guma, guar gume, tragantove gume, gume akacije, ksantan gume, gelan gume, alginskih derivata, alginske kiseline, natrijum alginata, polivinilpirolidona, od silikata, bentonita, laponita, veegum, specifičnije od ne-ionskih poloksamera, polivinilpirolidona i celulozni eteri, u količini od 0 do 15% tež/vol, npr.
The aqueous solution according to anyone of claims 1 to 11, wherein the at least one non-sugar type sweetener is selected from saccharin, saccharin salts, sodium saccharin, calcium saccharin, sucralose, potassium acetosulfam, stevioside, steviol, mannitol, erythritol, lactitol, maltitol, alitame, miraculin, monellin, thaumatin, and mixture thereof, and for example selected from saccharin sodium, and is in an amount of from 0.05 to 0.5% w/V. 
Otopina sukladno bilo kojem od patentnih zahtjeva 1 do 10, pri čemu je najmanje jedan zaslađivač tipa ne-šećer saharina, soli saharina, natrij saharin, kalcij saharin, sukraloze, kalij acesulfam, steviosida, steviol, manitol, eritritol, laktitola, maltitol, alitam, mirakulin, monelin, taumatin, i njihova smjesa, i primjerice odabran od saharin natrija u količini od 0.05 do 0.5% tež/vol.
The composition according to anyone of claims 1 to 13, wherein the beta-blocker is propranolol hydrochloride in an amount of 0.428 or 0.57 % w/V wherein the at least one sweetener is saccharin sodium in an amount of 0.15% w/V, wherein the at least one flavouring agent is a mixture of vanilla and strawberry flavour in an amount of 0.32% w/V the at least one viscosity increasing agent is hydroxyethylcellulose in an amount of 0.35 % w/V, and optionally comprising sodium propionate in an amount of 0.10% w/V. 
Otopina sukladno bilo kojem od patentnih zahtjeva 1 do 12, pri čemu propranolol ili njegove farmaceutski prihvatljive soli su propranolol hidroklorid u količini od 0.428 ili 0.57 % tež/vol pri čemu je najmanje jedno sladilo natrijev saharin u količini od 0.15% tež/vol, pri čemu je najmanje jedan agens za poboljšanje okusa smjesa vanilije i jagode u količini od 0.32% tež/vol i najmanje jedno sredstvo za povećanje viskoznosti je hidroksietilceluloza u količini od 0.35 % tež/zapr.
is -BC(O)NR13R14; wherein B is a bond, C1-C3-alkyl or branched C1-C3-alkyl; wherein R13 and R14 are each, independently, selected from the group consisting of hydrogen, C1-C3-allcyl, C3-C8-cycloalkyl, heterocyclyl, aryl, heteroaryl, substituted alkyl, substituted cycloalkyl, substituted heterocyclyl, substituted aryl, and substituted heteroaryl. 
je -BC(O)NR13R14; dok B je veza, C1-C3-alkil ili razgranati -C3-alkil; gdje je svaki od R13 i R14 neovisno odabran iz skupine koju čine: vodik, C1-C3-alkil, C3-C8-cikloalkil, heterociklil, aril, heteroaril, supstituirani alkil, supstituirani cikloalkil, supstituirani heterociklil, supstituirani aril i supstituirani heteroaril.